Stiles Financial Services Inc Grows Holdings in Novo Nordisk A/S $NVO

Stiles Financial Services Inc boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.9% in the 2nd quarter, HoldingsChannel reports. The firm owned 42,265 shares of the company’s stock after purchasing an additional 775 shares during the quarter. Novo Nordisk A/S makes up approximately 1.0% of Stiles Financial Services Inc’s portfolio, making the stock its 27th largest holding. Stiles Financial Services Inc’s holdings in Novo Nordisk A/S were worth $2,917,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of NVO. Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the last quarter. Rhumbline Advisers increased its stake in Novo Nordisk A/S by 10.2% in the first quarter. Rhumbline Advisers now owns 63,539 shares of the company’s stock worth $4,412,000 after purchasing an additional 5,898 shares during the period. Miracle Mile Advisors LLC purchased a new stake in Novo Nordisk A/S in the first quarter worth $278,000. GAMMA Investing LLC increased its stake in shares of Novo Nordisk A/S by 9.6% during the first quarter. GAMMA Investing LLC now owns 9,466 shares of the company’s stock valued at $657,000 after buying an additional 827 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Novo Nordisk A/S by 5.5% during the first quarter. SG Americas Securities LLC now owns 113,673 shares of the company’s stock valued at $7,893,000 after buying an additional 5,948 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $58.64 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The firm has a market capitalization of $261.83 billion, a P/E ratio of 16.11, a price-to-earnings-growth ratio of 2.70 and a beta of 0.68. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $120.56. The stock’s fifty day moving average is $55.26 and its two-hundred day moving average is $63.33.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s payout ratio is currently 22.53%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Barclays restated an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Dbs Bank upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Finally, BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target on the stock in a research note on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $77.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.